You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 藥明生物盤中大漲8%,報於41.8港元
uSMART盈立智投 10-26 10:28

2022年10月26日10時28分,藥明生物(HK02269)盤中大漲8%,報於41.8港元,成交額達12.51億港元,換手率達到0.62%。

10月26日訊,藥明生物(02269.HK)公佈,昨日(25日)回購300萬股,每股作價介乎38.2至38.85元,涉資約1.16億元。

10月11日,民生證券:維持藥明生物(02269)“推薦”評級,UVL清單移除釋放底部反轉信號。10月10日,中泰證券:維持藥明生物(02269)“買入”評級,看好CRDMO商業模式不斷兌現。10月10日,野村:維持藥明生物(02269)“買入”評級,目標價97.78港元。

最新的財務數據顯示,公司於2022年1季度,營業收入36.03億人民幣,淨利潤13.11億人民幣;營業收入同比增加63.53%,毛利潤同比增加49.08%,淨利潤同比增加39.22%。

盈立趨勢長盈模型最近一次交易信號,2022年10月20日出現觀望信號,觸發價格爲42.7港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account